title: Adiponectin receptor 1 enhances fatty acid metabolism and cell survival in palmitate-treated HepG2 cells through the PI3 K/AKT pathway.
abstract: OBJECTIVE
  Hepatic lipid overloading induces lipotoxicity which can cause hepatocyte damage, fibrosis, and eventually progress to cirrhosis, which is associated with nonalcoholic fatty liver disease. Adiponectin receptors play important roles in regulating lipid metabolism. In this study, we used a lentivirus system to overexpress the adiponectin receptor 1 (AdipoR1) in HepG2 cells to define the role of adiponectin and its receptor 1 in the development of fatty liver syndrome.
  
  
  RESULTS
  Exposure of human hepatocytes, HepG2 cells, to palmitate (0.2 or 0.4 mM) for 16 h resulted in elevated apoptosis, whereas AdipoR1 decreased the palmitate-induced apoptosis. Transgene AdipoR1 increased the expression of FATP2, acyl-coA oxidase, and carnitine palmitoyltransferase I in palmitate-treated HepG2 cells. The transcript level of acetyl-CoA carboxylase and fatty acid synthase was upregulated by palmitate treatment, while AdipoR1 reversed the effect induced by palmitate. AdipoR1 increased the gene expression of cytochrome C oxidase, peroxisome proliferator-activated receptor α, and decreased the gene expression of PGC1α and AMPKα in HepG2 cells under palmitate treatment. Palmitate suppressed ATP production, while transgene AdipoR1 reversed the decreased ATP production by palmitate. Transgene AdipoR1 enhanced AKT phosphorylation in HepG2 cells both with and without palmitate treatment. When PI3 kinase inhibitor was applied, the protective effect of AdipoR1 was absent, such that palmitate again decreased ATP production while also reducing cell viability.
  
  
  CONCLUSIONS
  AdipoR1 enhances fatty acid metabolism and cell viability in palmitate-treated HepG2 cells partially by activating AKT signaling. Therefore, AdipoR1 has therapeutic potential in the treatment of nonalcoholic fatty liver disease.
authors.affiliation: Department of Animal Science and Technology, National Taiwan University, 50, Lane 155, Sec 3, Keelung Rd, Taipei, 112, Taiwan.
authors.forename: I-Pin
authors.initials: IP
authors.lastname: Chou
authors.forename: Yuan Yu
authors.initials: YY
authors.lastname: Lin
authors.forename: Shih-Torng
authors.initials: ST
authors.lastname: Ding
authors.forename: Ching-Yi
authors.initials: CY
authors.lastname: Chen
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D052242:Adiponectin / Q000378:metabolism*; D000818:Animals; D017209:Apoptosis; D002470:Cell Survival / Q000187:drug effects; D004734:Energy Metabolism / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005230:Fatty Acids, Nonesterified / Q000009:adverse effects / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D056945:Hep G2 Cells; D022781:Hepatocytes / Q000166:cytology / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D006801:Humans; D019308:Palmitic Acid / Q000009:adverse effects / Q000378:metabolism; D058539:Phosphatidylinositol 3-Kinase / Q000378:metabolism*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010766:Phosphorylation / Q000187:drug effects; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D054419:Receptors, Adiponectin / Q000819:agonists* / Q000235:genetics / Q000378:metabolism; D011994:Recombinant Proteins / Q000737:chemistry / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D034421:Sus scrofa
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; D004791:Enzyme Inhibitors; D005230:Fatty Acids, Nonesterified; D000081082:Phosphoinositide-3 Kinase Inhibitors; D054419:Receptors, Adiponectin; D011994:Recombinant Proteins; D019308:Palmitic Acid; D000255:Adenosine Triphosphate; D058539:Phosphatidylinositol 3-Kinase; C494918:AKT1 protein, human; D051057:Proto-Oncogene Proteins c-akt